Stryker's DAWN Thrombectomy Trial Could Also Help Medtronic And Penumbra

Sales of mechanical thrombectomy systems are poised to get a boost from the published results of the DAWN trial, which showed outcomes for disability are better with thrombectomy plus standard medical care than with standard medical care alone in the subset of acute stroke patients who are treated six to 24 hours after onset and show a mismatch between the severity of the clinical deficit and the infarct volume.

"The DAWN data has already boosted the growth rate of the mechanical thrombectomy market," Wells Fargo analyst Larry Biegelsen writes in a Nov 12 note. He estimates that mechanical thrombectomy...